- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00697996
Rituximab for Pediatric Renal Transplant Rejection
A Prospective Open-Labeled Randomized Study of Rituximab Versus Standard of Care, for Treatment of Acute Allograft Rejection in Pediatric Renal Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Twenty kidney transplant recipients who are being cared for at Stanford University and UCLA and are between the ages of 2-21, can be considered for participation in this research if they are having an acute rejection episode. After a biopsy is done and the diagnosis of acute rejection is made, ten patients will be randomly enrolled in the group to be treated with Rituximab and steroid pulses. Ten children will be enrolled as the control group, receiving standard of care for acute transplant rejection.
Assignment will be based on a 1:1 randomization scheme. That means two patients will be assigned to the group of patients receiving steroid pulsing and 4 doses of Rituximab. The third patient would be assigned to the group receiving steroid pulses and adjustment in immunosuppression medications which is the standard of care at Stanford University.
The dose of Rituximab that will be given is 375 mg/m2 and is administered through an IV. Additional doses of Rituximab will be administered on a weekly basis. A total of four doses will be given.
If the acute rejection does not resolve by one-week, patients in both groups have the option of receiving polyclonal antibody therapy.
Study Type
Enrollment
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:Patients must meet the following inclusion criteria to be eligible for study entry:
- Pediatric renal allograft recipients aged 2-21 years with biopsy proven acute rejection episodes.
- Able and willing to give written informed consent and comply with the requirements of the study protocol (patients >18 years of age or parents)
- Greater than 30% decline in baseline renal function as indicated by a rise in the serum creatinine.
- Adequate liver function, as indicated by AST or ALT <2x upper limit of normal unless related to primary disease.
- Negative serum pregnancy test (for women of child bearing age)
- Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months (1 year) after completion of treatment.
Exclusion Criteria:Patients will be excluded from the study based on the following criteria:
- Treatment with any investigational agent within 4 weeks of screening or 5 half-lives of the investigational drug (whichever is longer)
- Receipt of a live vaccine within 4 weeks prior to randomization
- Previous Treatment with Rituximab (MabThera® / Rituxan®)
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
- History of HIV (positive HIV, HIV conducted during screening if applicable)
- History of Hepatitis B and/or Hepatitis C (Hep B/C at screening)
- History of recurrent significant infection or history of recurrent bacterial infections
- Known active bacterial, viral, fungal, mycobacterial, or other infection (including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening
- Ongoing use of high dose steroids (>10mg/day) or unstable steroid dose in the past 4 weeks.
- Lack of peripheral venous access
- History of drug, alcohol, or chemical abuse within 6 months prior to screening
- Pregnancy (a negative serum pregnancy test should be performed for all women of childbearing potential within 7 days of treatment) or lactation
- Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
- History of psychiatric disorder
- Significant cardiac or pulmonary disease (including obstructive pulmonary disease)
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
- Inability to comply with study and follow-up procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Rituximab safety in pediatric patients
|
Secondary Outcome Measures
Outcome Measure |
---|
resolution fo graft rejection
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Minnie M. Sarwal, Stanford University
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SU-06102008-1196
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Nantes University HospitalTerminated
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on Rituximab for transplant rejection
-
Exosome Diagnostics, Inc.Not yet recruitingGraft Rejection
-
Yale UniversityTerminatedDe Novo Autoimmune Hepatitis
-
Policlinico HospitalCompletedLung Transplant | Right Ventricular FailureItaly
-
Amy FinkelsteinMassachusetts Institute of TechnologyCompletedEnd Stage Renal DiseaseUnited States
-
CellTrans Inc.Approved for marketingType 1 Diabetes MellitusUnited States
-
Enzyvant Therapeutics GmBHTerminatedPhase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus TransplantationStem Cell TransplantationUnited States
-
Fondazione Italiana Linfomi ONLUSUnknown
-
Centre Hospitalier Universitaire de NiceInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Akdeniz UniversityRecruitingMedication Adherence | Kidney Transplantation | Treatment Adherence | Motivational Interviewing | Patient Outcome Assessment | Self-Management | AdultTurkey
-
Duke UniversityHaller FoundationCompletedMedication Adherence | Patient Satisfaction | Kidney Transplant; Complications | Patient EmpowermentUnited States